Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site
- 16 November 2015
- journal article
- research article
- Published by Springer Nature in Investigational New Drugs
- Vol. 34 (1) , 41-48
Abstract
Summary Introduction Pazopanib exhibits wide inter-patient pharmacokinetic variability which may contribute to differences in treatment outcome. Unbound drug concentrations are believed to be more relevant to pharmacological responses than total concentrations. Thus it is desirable to evaluate pazopanib binding on plasma proteins and different factors potentially affecting this process. Methods An equilibrium dialysis method coupled with UPLC-MS/MS assay has been optimized and validated for the determination of pazopanib unbound fraction (fu%) in human plasma. Pazopanib binding in the plasma of healthy volunteers and in isolated protein solutions was investigated. The unbound fraction was determined for 24 cancer patients treated daily with pazopanib. Results We found that pazopanib was extensively bound in human plasma (>99.9 %) with a mean fu% value of 0.0106 ± 0.0013 % at 40 μg/mL. Protein binding was concentration independent over a clinically relevant range of concentrations. In isolated protein solutions, pazopanib at 40 μg/mL was mainly bound to albumin (40 g/L) and to a lesser extent to α1-acid glycoprotein (1 g/L) and low density lipoproteins (1.2 g/L), with a mean fu% of 0.0073 ± 0.0022 %, 0.992 ± 0.44 % and 7.4 ± 1.7 % respectively. Inter-patient variability (CV%) of fu% in cancer patients was limited (27.2 %). A correlation was observed between individual unbound fraction values and albuminemia. Conclusions Pazopanib exhibits extensive binding to plasma proteins in human plasma. Variable albumin concentrations, frequently observed in cancer patients, may affect pazopanib unbound fraction with implications for inter-patient variability in drug efficacy and toxicity.Keywords
Funding Information
- Allocation Jeunes Chercheurs GIRCI-SOOM
This publication has 25 references indexed in Scilit:
- Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethyl-imatinib be developed?Cancer Chemotherapy and Pharmacology, 2012
- Determination of unbound fraction of imatinib and N-desmethyl imatinib, validation of an UPLC–MS/MS assay and ultrafiltration methodJournal of Chromatography B, 2012
- Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patientsInvestigational New Drugs, 2011
- Phase I Dose-Finding Study of Pazopanib in Hepatocellular Carcinoma: Evaluation of Early Efficacy, Pharmacokinetics, and PharmacodynamicsClinical Cancer Research, 2011
- The European Medicines Agency Review of Pazopanib for the Treatment of Advanced Renal Cell Carcinoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human UseClinical Cancer Research, 2011
- PazopanibDrugs, 2011
- (Pre-)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis InhibitorThe Oncologist, 2010
- Validation of a Rapid Equilibrium Dialysis Approach for the Measurement of Plasma Protein BindingJournal of Pharmaceutical Sciences, 2008
- Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patientsInvestigational New Drugs, 2006
- Drug Binding in PlasmaClinical Pharmacokinetics, 1994